This study is looking into whether an investigational drug called activin ligand-trap biological therapy, combined with exercise, can help people with a type of heart failure called Heart Failure with Preserved Ejection Fraction (HFpEF). HFpEF means your heart pumps blood normally, but it's too stiff to fill properly. Researchers want to see if this treatment can improve your ability to exercise (measured by how much oxygen your body uses during activity) and your thinking skills. You might be eligible if you are at least 40 years old, have HFpEF, and are overweight or obese. The study aims to enroll 48 participants, but its current status is unclear.

Study design

This is a randomized, placebo-controlled study where 48 participants will be assigned by chance to receive either activin ligand-trap biological therapy or an inactive drug (placebo), both combined with physical activity. It is a double-blind study, meaning neither you nor the researchers will know which treatment you are receiving.

What's involved

You would undergo several tests at the beginning, including exercise tests, blood work, body scans, and questionnaires. You would then receive treatment for 12 weeks, followed by another round of tests, and then continue in the study for a total of 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your exercise capacity and cognitive function will be measured at 12 weeks and again at 24 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.